Handel Caribou Biosciences, Inc. - CRBU CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Handelsbetingelser
| Spænd | 0.05 | ||||||||
|
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.024068% | ||||||||
|
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.001846% | ||||||||
| Gebyr natten over, tid | 21:00 (UTC) | ||||||||
| Min. handlet mængde | 1 | ||||||||
| Valuta | USD | ||||||||
| Margen | 20% | ||||||||
| Aktiebørs | United States of America | ||||||||
| Kommission på handel | 0% |
*Information provided by Capital.com
Nøglestatistikker
| Tidligere luk* | 4.93 |
| Åben* | 4.8 |
| 1-Års Ændring* | -50.82% |
| Dagens Spænd* | 4.71 - 4.86 |
| 52-Ugers Spænd | 4.83-13.19 |
| Gennemsnitlig Volumen (10 dage) | 595.92K |
| Gennemsnitlig Volumen (3 måneder) | 10.45M |
| Market Cap | 304.05M |
| P/E-forhold | -100.00K |
| Udestående aktier | 61.30M |
| Omsætning | 13.85M |
| EPS | -1.63 |
| Dividend (Udbytte %) | N/A |
| Beta | -100.00K |
| Næste indtjeningsopgørelse | N/A |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Luk | Change | Change (%) | Åben | High | Low |
|---|---|---|---|---|---|---|
| Mar 17, 2023 | 4.91 | -0.02 | -0.41% | 4.93 | 5.02 | 4.80 |
| Mar 16, 2023 | 5.02 | -0.07 | -1.38% | 5.09 | 5.15 | 4.91 |
| Mar 15, 2023 | 5.15 | 0.10 | 1.98% | 5.05 | 5.25 | 5.02 |
| Mar 14, 2023 | 5.18 | -0.25 | -4.60% | 5.43 | 5.51 | 5.10 |
| Mar 13, 2023 | 5.30 | 0.25 | 4.95% | 5.05 | 5.34 | 5.02 |
| Mar 10, 2023 | 5.14 | -0.29 | -5.34% | 5.43 | 5.48 | 4.93 |
| Mar 9, 2023 | 5.48 | -0.35 | -6.00% | 5.83 | 5.85 | 5.33 |
| Mar 8, 2023 | 5.85 | 0.02 | 0.34% | 5.83 | 5.92 | 5.75 |
| Mar 7, 2023 | 5.86 | 0.03 | 0.51% | 5.83 | 6.04 | 5.70 |
| Mar 6, 2023 | 5.77 | -0.32 | -5.25% | 6.09 | 6.09 | 5.54 |
| Mar 3, 2023 | 6.09 | 0.17 | 2.87% | 5.92 | 6.11 | 5.86 |
| Mar 2, 2023 | 5.89 | 0.01 | 0.17% | 5.88 | 5.98 | 5.82 |
| Mar 1, 2023 | 6.00 | 0.03 | 0.50% | 5.97 | 6.13 | 5.88 |
| Feb 28, 2023 | 6.06 | 0.17 | 2.89% | 5.89 | 6.17 | 5.88 |
| Feb 27, 2023 | 5.97 | 0.16 | 2.75% | 5.81 | 6.09 | 5.78 |
| Feb 24, 2023 | 5.76 | -0.14 | -2.37% | 5.90 | 5.94 | 5.70 |
| Feb 23, 2023 | 6.07 | -0.12 | -1.94% | 6.19 | 6.23 | 5.93 |
| Feb 22, 2023 | 6.17 | 0.07 | 1.15% | 6.10 | 6.24 | 5.98 |
| Feb 21, 2023 | 6.09 | -0.39 | -6.02% | 6.48 | 6.73 | 6.08 |
| Feb 17, 2023 | 6.82 | 0.33 | 5.08% | 6.49 | 6.83 | 6.36 |
Caribou Biosciences, Inc. Events
| Tid (UTC) (UTC) | Land | Begivenhed |
|---|---|---|
| No events scheduled | ||
- Årlig
- Pr kvartal
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Total omsætning | 5.788 | 12.361 | 9.598 |
| Omsætning | 5.788 | 12.361 | 9.598 |
| Totale Driftsudgifter | 40.093 | 48.485 | 74.993 |
| Salgs/Generelle/Admin. Udgifter, Total | 16.458 | 14.06 | 24.322 |
| Forskning & Udvikling | 23.635 | 34.425 | 52.255 |
| Driftsindtægter | -34.305 | -36.124 | -65.395 |
| Renteindkomst (Udgift), Netto Ikke-Drift | 3.337 | -0.517 | 0.14 |
| Andre, Netto | 0 | 0.514 | -1.347 |
| Netto Indkomst Før Skat | -30.968 | -36.127 | -66.602 |
| Netto Indkomst Efter Skat | -23.431 | -34.308 | -66.923 |
| Netto Indkomst Før Ekstra Ting | -23.431 | -34.308 | -66.923 |
| Netto Indkomst | -23.431 | -34.308 | -66.923 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -23.431 | -34.308 | -66.923 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -23.431 | -34.308 | -66.923 |
| Fortyndet Netto Indkomst | -23.431 | -34.308 | -66.923 |
| Fortyndet Vægtet Gennemsnit Aktier | 56.7092 | 56.7092 | 31.6632 |
| Fortyndet EPS Uden Ekstraordinære Ting | -0.41318 | -0.60498 | -2.11359 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 |
| Fortyndet Normaliseret EPS | -0.41318 | -0.60498 | -2.1461 |
| Usædvanlig Udgift (Indkomst) | -1.584 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Total omsætning | 1.586 | 1.476 | 3.977 | 2.559 | 2.664 |
| Omsætning | 1.586 | 1.476 | 3.977 | 2.559 | 2.664 |
| Totale Driftsudgifter | 14.761 | 15.856 | 22.593 | 22.964 | 23.517 |
| Salgs/Generelle/Admin. Udgifter, Total | 4.596 | 5.113 | 6.76 | 7.853 | 9.593 |
| Forskning & Udvikling | 10.165 | 12.327 | 15.833 | 15.111 | 13.924 |
| Driftsindtægter | -13.175 | -14.38 | -18.616 | -20.405 | -20.853 |
| Renteindkomst (Udgift), Netto Ikke-Drift | -0.001 | 0.044 | 0.022 | 0.076 | 0.163 |
| Andre, Netto | 0.017 | 0.025 | -2.38 | 2.171 | 1.602 |
| Netto Indkomst Før Skat | -13.159 | -14.311 | -20.974 | -18.158 | -19.088 |
| Netto Indkomst Efter Skat | -13.159 | -14.311 | -20.974 | -18.479 | -19.088 |
| Netto Indkomst Før Ekstra Ting | -13.159 | -14.311 | -20.974 | -18.479 | -19.088 |
| Netto Indkomst | -13.159 | -14.311 | -20.974 | -18.479 | -19.088 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -13.159 | -14.311 | -20.974 | -18.479 | -19.088 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -13.159 | -14.311 | -20.974 | -18.479 | -19.088 |
| Fortyndet Netto Indkomst | -13.159 | -14.311 | -20.974 | -18.479 | -19.088 |
| Fortyndet Vægtet Gennemsnit Aktier | 56.7092 | 10.2618 | 45.8896 | 60.4941 | 60.5462 |
| Fortyndet EPS Uden Ekstraordinære Ting | -0.23204 | -1.39459 | -0.45705 | -0.30547 | -0.31526 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
| Fortyndet Normaliseret EPS | -0.23204 | -1.54895 | -0.45705 | -0.30547 | -0.31526 |
| Usædvanlig Udgift (Indkomst) | -1.584 | 0 | 0 |
- Årlig
- Pr kvartal
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Totale Nuværende Aktiver | 57.008 | 24.306 | 391.192 |
| Likvider og Kortsigtede Investeringer | 49.471 | 15.953 | 375.832 |
| Likvider & Lignende | 41.07 | 15.953 | 240.42 |
| Kortsigtede Investeringer | 8.401 | 0 | 135.412 |
| Totale Tilgodehavender, Netto | 3.982 | 5.16 | 8.124 |
| Accounts Receivable - Trade, Net | 0.841 | 1.478 | 2.641 |
| Prepaid Expenses | 3.182 | 2.433 | 6.565 |
| Other Current Assets, Total | 0.373 | 0.76 | 0.671 |
| Total Assets | 61.933 | 36.046 | 442.356 |
| Property/Plant/Equipment, Total - Net | 4.332 | 3.502 | 4.887 |
| Property/Plant/Equipment, Total - Gross | 6.59 | 6.598 | 8.964 |
| Accumulated Depreciation, Total | -2.258 | -3.096 | -4.077 |
| Long Term Investments | 0 | 7.626 | 45.302 |
| Other Long Term Assets, Total | 0.593 | 0.612 | 0.975 |
| Total Current Liabilities | 10.078 | 12.389 | 25.829 |
| Accounts Payable | 2.537 | 2.601 | 3.99 |
| Accrued Expenses | 5.653 | 8.151 | 12.089 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0.654 | 0 |
| Other Current Liabilities, Total | 1.888 | 0.983 | 9.75 |
| Total Liabilities | 13.147 | 18.16 | 54.531 |
| Total Long Term Debt | 0 | 0.924 | 0 |
| Long Term Debt | 0 | 0.924 | 0 |
| Deferred Income Tax | 0.65 | 0.155 | 0.476 |
| Other Liabilities, Total | 2.419 | 4.692 | 28.226 |
| Total Equity | 48.786 | 17.886 | 387.825 |
| Preferred Stock - Non Redeemable, Net | 41.323 | 41.323 | 0 |
| Common Stock | 0.001 | 0.001 | 0.006 |
| Additional Paid-In Capital | 4.025 | 7.433 | 485.748 |
| Retained Earnings (Accumulated Deficit) | 3.437 | -30.871 | -97.794 |
| Total Liabilities & Shareholders’ Equity | 61.933 | 36.046 | 442.356 |
| Total Common Shares Outstanding | 56.7092 | 56.7092 | 60.2632 |
| Other Equity, Total | -0.135 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 155.925 | 142.967 | 449.047 | 391.192 | 368.01 |
| Likvider og Kortsigtede Investeringer | 145.924 | 129.524 | 435.31 | 375.832 | 353.731 |
| Likvider & Lignende | 145.924 | 129.524 | 435.31 | 240.42 | 147.63 |
| Totale Tilgodehavender, Netto | 5.825 | 8.407 | 7.785 | 8.124 | 6.037 |
| Accounts Receivable - Trade, Net | 1.049 | 0.832 | 2.431 | 2.641 | 1.868 |
| Prepaid Expenses | 3.096 | 3.759 | 5.189 | 6.565 | 7.276 |
| Other Current Assets, Total | 1.08 | 1.277 | 0.763 | 0.671 | 0.966 |
| Total Assets | 167.965 | 158.397 | 461.96 | 442.356 | 445.997 |
| Property/Plant/Equipment, Total - Net | 3.38 | 4.408 | 4.477 | 4.887 | 31.765 |
| Property/Plant/Equipment, Total - Gross | 6.695 | 7.952 | 8.282 | 8.964 | 36.15 |
| Accumulated Depreciation, Total | -3.315 | -3.544 | -3.805 | -4.077 | -4.385 |
| Long Term Investments | 7.626 | 7.626 | 7.626 | 45.302 | 44.758 |
| Other Long Term Assets, Total | 1.034 | 3.396 | 0.81 | 0.975 | 1.464 |
| Total Current Liabilities | 22.21 | 26.007 | 26.158 | 25.829 | 26.667 |
| Accounts Payable | 3.117 | 4.029 | 3.482 | 3.99 | 1.814 |
| Accrued Expenses | 10.929 | 11.034 | 12.288 | 12.089 | 11.215 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.655 | 0 | 0 | 0 | |
| Other Current Liabilities, Total | 7.509 | 10.944 | 10.388 | 9.75 | 13.638 |
| Total Liabilities | 53.504 | 55.938 | 57.559 | 54.531 | 74.2 |
| Total Long Term Debt | 0.926 | 0 | 0 | 0 | 0 |
| Long Term Debt | 0.926 | 0 | 0 | 0 | |
| Deferred Income Tax | 0.155 | 0.155 | 0.155 | 0.476 | 0.476 |
| Other Liabilities, Total | 30.213 | 29.776 | 31.246 | 28.226 | 47.057 |
| Total Equity | 114.461 | 102.459 | 404.401 | 387.825 | 371.797 |
| Preferred Stock - Non Redeemable, Net | 150.15 | 150.15 | 0 | 0 | 0 |
| Common Stock | 0.001 | 0.001 | 0.006 | 0.006 | 0.006 |
| Additional Paid-In Capital | 8.34 | 10.649 | 483.71 | 485.748 | 489.762 |
| Retained Earnings (Accumulated Deficit) | -44.03 | -58.341 | -79.315 | -97.794 | -116.882 |
| Total Liabilities & Shareholders’ Equity | 167.965 | 158.397 | 461.96 | 442.356 | 445.997 |
| Total Common Shares Outstanding | 56.7092 | 59.9708 | 60.0213 | 60.2632 | 60.6896 |
| Kortsigtede Investeringer | 135.412 | 206.101 | |||
| Other Equity, Total | -0.135 | -1.089 |
- Årlig
- Pr kvartal
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Netto indkomst/Startlinje | -23.431 | -34.308 | -66.923 |
| Likvider Fra Driftsaktiviteter | -32.006 | -33.215 | -32.519 |
| Likvider Fra Driftsaktiviteter | 0.751 | 0.9 | 0.984 |
| Ikke-Likvide Ting | -1.059 | 0.016 | 4.353 |
| Cash Taxes Paid | 1.809 | 0.021 | 0.011 |
| Ændringer i Driftskapital | -8.267 | 0.177 | 29.067 |
| Likvider fra Investeringsaktiviteter | 27.233 | 6.363 | -176.397 |
| Kapitaludgifter | -0.884 | -0.317 | -2.121 |
| Andre Investerings-Cash-Flow-Ting, Total | 28.117 | 6.68 | -174.276 |
| Likvider fra Financieringsaktiviteter | 0.172 | 1.735 | 433.429 |
| Udstedelse (Pensionering) af Aktier, Netto | 0.217 | 1.848 | 432.398 |
| Udstedelse (Pensionering) af Gæld, Netto | -0.045 | -0.113 | 1.031 |
| Netto Ændring i Likviditet | -4.601 | -25.117 | 224.513 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -13.159 | -27.47 | -48.444 | -66.923 | -19.088 |
| Cash From Operating Activities | 20.313 | 3.837 | -11.13 | -32.519 | -21.673 |
| Cash From Operating Activities | 0.221 | 0.451 | 0.711 | 0.984 | 0.308 |
| Non-Cash Items | 1.036 | 1.542 | 4.88 | 4.353 | 2.215 |
| Cash Taxes Paid | 0 | 0.011 | 0.011 | 0.011 | 0 |
| Cash Interest Paid | 0.001 | 0 | |||
| Changes in Working Capital | 32.215 | 29.314 | 31.723 | 29.067 | -5.108 |
| Cash From Investing Activities | -0.022 | -0.506 | -2.436 | -176.397 | -72.107 |
| Capital Expenditures | -0.022 | -0.506 | -1.436 | -2.121 | -0.723 |
| Other Investing Cash Flow Items, Total | 0 | 0 | -1 | -174.276 | -71.384 |
| Cash From Financing Activities | 109.68 | 110.286 | 432.969 | 433.429 | 0.99 |
| Issuance (Retirement) of Stock, Net | 109.799 | 109.957 | 431.938 | 432.398 | 0.99 |
| Issuance (Retirement) of Debt, Net | -0.119 | 1.031 | 1.031 | 1.031 | 0 |
| Net Change in Cash | 129.971 | 113.617 | 419.403 | 224.513 | -92.79 |
| Financing Cash Flow Items | -0.702 |
| Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
|---|---|---|---|---|---|---|
| PFM Health Sciences, LP | Hedge Fund | 7.2754 | 4459783 | -1540217 | 2022-12-31 | MED |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.6832 | 4096777 | 277588 | 2022-12-31 | LOW |
| Haurwitz (Rachel E. Ph.D.) | Individual Investor | 5.4966 | 3369395 | 0 | 2022-08-01 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.2184 | 3198893 | 803423 | 2022-12-31 | LOW |
| Avidity Partners Management LP | Hedge Fund | 4.7025 | 2882600 | -290000 | 2022-12-31 | HIGH |
| Rokos Capital Management LLP | Hedge Fund | 4.4831 | 2748139 | 840630 | 2022-12-31 | HIGH |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.1939 | 2570827 | 26789 | 2022-12-31 | LOW |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 4.1662 | 2553878 | -737020 | 2022-12-31 | LOW |
| Elmwood Wealth Management, INC. | Investment Advisor | 3.8569 | 2364240 | 0 | 2022-12-31 | LOW |
| EIDP Inc | Corporation | 3.3573 | 2058000 | -1093311 | 2022-05-31 | MED |
| BofA Global Research (US) | Research Firm | 3.008 | 1843902 | 1668395 | 2022-12-31 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 2.3541 | 1443046 | -547 | 2022-12-31 | LOW |
| Morgan Stanley & Co. LLC | Research Firm | 1.982 | 1214933 | 30615 | 2022-12-31 | MED |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.6819 | 1030987 | 45617 | 2022-12-31 | LOW |
| Alkeon Capital Management LLC | Investment Advisor/Hedge Fund | 1.4575 | 893424 | -138016 | 2022-12-31 | LOW |
| Fidelity International | Investment Advisor | 1.404 | 860666 | 0 | 2022-12-31 | LOW |
| Assenagon Asset Management S.A. | Investment Advisor | 1.3944 | 854738 | 55247 | 2022-12-31 | HIGH |
| Maverick Capital, Ltd. | Hedge Fund | 1.0645 | 652542 | 0 | 2022-12-31 | MED |
| Tekla Capital Management LLC | Investment Advisor | 0.9252 | 567147 | 0 | 2022-12-31 | LOW |
| JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 0.9215 | 564855 | -1059 | 2022-12-31 | LOW |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group 500000+
Handlende
92000+
Månedlkige, aktive klienter
$53000000+
Månedlig investeringsvolumen
$30000000+
Prøv nu Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
Handelskurtage
0
- 1:1
Gearing
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben
Luk
Short Long
Caribou Biosciences, Inc. Company profile
Om Caribou Biosciences, Inc.
Caribou Biosciences, Inc. er en amerikansk bioteknologisk virksomhed i den kliniske fase i USA. Virksomheden anvender CRISPR (clustered regularly interspaced short palindromic repeats) genomredigering til at opdage og udvikle immuncellebaserede terapier mod kræft. Selskabet er fokuseret på at udvikle en pipeline af genomredigerede, standardiserede CAR-T-celle- og NK-cellebehandlinger (natural killer (NK)-behandlinger) til behandling af en række tumortyper. Selskabet tilbyder også licenser til sin grundlæggende CRISPR-Cas9-IP på flere områder, herunder forskningsværktøjer, intern forskningsanvendelse, diagnostik og industriel bioteknologi. Virksomhedens pipeline omfatter CB-010, CB-011, CB-012 og CB-020.
| Industry: | Biotechnology & Medical Research (NEC) |
2929 7Th Street, Ste 120
94710
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com